相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models
Elizabeth E. Spangenberg et al.
BRAIN BEHAVIOR AND IMMUNITY (2017)
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Eric R. Siemers et al.
ALZHEIMERS & DEMENTIA (2016)
Impairment of blood brain barrier is related with the neuroinflammation induced peripheral immune status in intracerebroventricular colchicine injected rats: An experimental study with mannitol
Susmita Sil et al.
BRAIN RESEARCH (2016)
Pentameric Models as Alternative Molecular Targets for the Design of New Antiaggregant Agents
Exequiel E. Barrera Guisasola et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2016)
Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain
Kapil Gadkar et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease
Marielle Delnomdedieu et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials
Rik Vandenberghe et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
Safety and tolerability of BAN2401-a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody
Veronika Logovinsky et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
Structure of ring-shaped Aβ42 oligomers determined by conformational selection
Linh Tran et al.
SCIENTIFIC REPORTS (2016)
Neurodegenerative Diseases: Expanding the Prion Concept
Lary C. Walker et al.
ANNUAL REVIEW OF NEUROSCIENCE, VOL 38 (2015)
Antibody therapies and their challenges in the treatment of age-related macular degeneration
Cornelia Volz et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2015)
Prefibrillar huntingtin oligomers isolated from HD brain potently seed amyloid formation
Olga A. Morozova et al.
FEBS LETTERS (2015)
Immunotherapeutic Approaches for Alzheimer's Disease
Thomas Wisniewski et al.
NEURON (2015)
Interaction between therapeutic interventions for Alzheimer's disease and physiological Aβ clearance mechanisms
Christopher D. Morrone et al.
FRONTIERS IN AGING NEUROSCIENCE (2015)
Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer's disease and cerebral amyloid angiopathy
Jacopo C. DiFrancesco et al.
FRONTIERS IN NEUROLOGY (2015)
Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases
Marta Westwood et al.
ANTIBODIES (2015)
Recombinant antibody production evolves into multiple options aimed at yielding reagents suitable for application-specific needs
Ario de Marco
MICROBIAL CELL FACTORIES (2015)
Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies
Anna Bogstedt et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE
Jeffrey Cummings et al.
Alzheimers & Dementia (2014)
A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease
Eric Karran et al.
ANNALS OF NEUROLOGY (2014)
The Structure of Misfolded Amyloidogenic Dimers: Computational Analysis of Force Spectroscopy Data
Yuliang Zhang et al.
BIOPHYSICAL JOURNAL (2014)
Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Kris Simone Tranches Dias et al.
Current Neuropharmacology (2014)
Clinical Trials of Intravenous Immunoglobulin for Alzheimer's Disease
Norman Relkin
JOURNAL OF CLINICAL IMMUNOLOGY (2014)
Amyloid-β-directed immunotherapy for Alzheimer's disease
L. Lannfelt et al.
JOURNAL OF INTERNAL MEDICINE (2014)
X-ray Crystallographic Structures of Trimers and Higher-Order Oligomeric Assemblies of a Peptide Derived from Aβ17-36
Ryan K. Spencer et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease
Shichun Tu et al.
MOLECULAR NEURODEGENERATION (2014)
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study
Thomas Leyhe et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics
William F. Goure et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease
Lars Lannfelt et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
The genetics of Alzheimer's disease
Eva Bagyinszky et al.
CLINICAL INTERVENTIONS IN AGING (2014)
The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries
Johan Lundkvist et al.
FRONTIERS IN PHARMACOLOGY (2014)
ACU-193: A candidate therapeutic antibody that selectively targets soluble beta-amyloid oligomers
Grant Krafft et al.
Alzheimers & Dementia (2013)
Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study
Izuru Miyoshi et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
Mouse platforms jostle for slice of humanized antibody market
Nuala Moran
NATURE BIOTECHNOLOGY (2013)
SYNAPTIC CHANGES IN ALZHEIMER'S DISEASE AND ITS MODELS
J. Pozueta et al.
NEUROSCIENCE (2013)
Cu2+ Affects Amyloid-β (1-42) Aggregation by Increasing Peptide-Peptide Binding Forces
Francis Hane et al.
PLOS ONE (2013)
Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation
Luke A. Miles et al.
SCIENTIFIC REPORTS (2013)
Evidence for impaired amyloid beta clearance in Alzheimer's disease
Kristin R. Wildsmith et al.
ALZHEIMERS RESEARCH & THERAPY (2013)
Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
Jens Moreth et al.
IMMUNITY & AGEING (2013)
Aβ(39-42) Modulates Aβ Oligomerization but Not Fibril Formation
Megan Murray Gessel et al.
BIOCHEMISTRY (2012)
The Amyloid Beta Peptide: A Chemist's Perspective. Role in Alzheimer's and Fibrillization
I. W. Hamley
CHEMICAL REVIEWS (2012)
The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders II: Alzheimers Disease
Miguel Divino da Rocha et al.
CNS & Neurological Disorders-Drug Targets (2012)
Soluble A ss oligomer production and toxicity
Megan E. Larson et al.
JOURNAL OF NEUROCHEMISTRY (2012)
An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ
Oskar Adolfsson et al.
JOURNAL OF NEUROSCIENCE (2012)
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
Ronald B. DeMattos et al.
NEURON (2012)
Large Aggregates Are the Major Soluble Ab Species in AD Brain Fractionated with Density Gradient Ultracentrifugation
Dag Sehlin et al.
PLOS ONE (2012)
Structure-based design of conformation- and sequence-specific antibodies against amyloid β
Joseph M. Perchiacca et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Molecular basis of β-amyloid oligomer recognition with a conformational antibody fragment
Isabel Morgado et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Y. Joy Yu et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Characterization of the Interaction of β-Amyloid with Transthyretin Monomers and Tetramers
Jiali Du et al.
BIOCHEMISTRY (2010)
Polymorphism in Alzheimer Aβ Amyloid Organization Reflects Conformational Selection in a Rugged Energy Landscape
Yifat Miller et al.
CHEMICAL REVIEWS (2010)
Amyloid-β Immunotherapy for Alzheimer's Disease
H. J. Fu et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2010)
Microglia and Inflammation in Alzheimer's Disease
Shweta Mandrekar-Colucci et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2010)
Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio
Irina Kuperstein et al.
EMBO JOURNAL (2010)
Bapineuzumab
Geoffrey A. Kerchner et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Generation and Therapeutic Efficacy of Highly Oligomer-Specific β-Amyloid Antibodies
Heinz Hillen et al.
JOURNAL OF NEUROSCIENCE (2010)
Transmembrane Structures for Alzheimer's Aβ1-42 Oligomers
Birgit Strodel et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
Restricted V gene usage and VH/VL pairing of mouse humoral response against the N terminal immunodominant epitope of the amyloid β peptide
Remy Robert et al.
MOLECULAR IMMUNOLOGY (2010)
Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers
Rakez Kayed et al.
MOLECULAR NEURODEGENERATION (2010)
Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons
P. J. Shughrue et al.
NEUROBIOLOGY OF AGING (2010)
Beneficial Catalytic Immunity to Aβ Peptide
Sudhir Paul et al.
REJUVENATION RESEARCH (2010)
A fibril-specific, conformation-dependent antibody recognizes a subset of Aβ plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain
Floyd Sarsoza et al.
ACTA NEUROPATHOLOGICA (2009)
Abeta-oligomer selective antibody A-887755 exhibits a favorable profile for Alzheimer's disease immunotherapy compared to Abeta-peptide unselective antibodies
Stefan Barghorn et al.
Alzheimers & Dementia (2009)
Polymorphism of Alzheimer's Aβ17-42 (p3) Oligomers: The Importance of the Turn Location and Its Conformation
Yifat Miller et al.
BIOPHYSICAL JOURNAL (2009)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
Structure-neurotoxicity relationships of amyloid β-protein oligomers
Kenjiro Ono et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Energy landscapes of the monomer and dimer of the Alzheimer's peptide Aβ(1-28)
Xiao Dong et al.
JOURNAL OF CHEMICAL PHYSICS (2008)
Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools
Peter Lichtlen et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Amyloid β protein dimer-containing human CSF disrupts synaptic plasticity:: Prevention by systemic passive immunization
Igor Klyubin et al.
JOURNAL OF NEUROSCIENCE (2008)
Computational study on the structural diversity of amyloid beta peptide (Aβ10-35) oligomers
Soonmin Jang et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2008)
Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer's disease
Melanie Meyer-Luehmann et al.
NATURE (2008)
Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice
Ivo Cristiano Martins et al.
EMBO JOURNAL (2008)
Forecasting the global burden of Alzheimer's disease
Ron Brookmeyer et al.
ALZHEIMERS & DEMENTIA (2007)
Amyloid-β in Alzheimer disease:: The null versus the alternate hypotheses
Hyoung-gon Lee et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease
Pascale N. Lacor et al.
JOURNAL OF NEUROSCIENCE (2007)
Monoclonal antibodies that target pathological assemblies of A beta
Mary P. Lambert et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Solution state characterization of amyloid β-derived diffusible ligands
Robert W. Hepler et al.
BIOCHEMISTRY (2006)
Deglycosylated anti-amyloid-β antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice
Donna M. Wilcock et al.
JOURNAL OF NEUROSCIENCE (2006)
Globular amyloid β-peptide1-42 oligomer -: a homogenous and stable neuropathological protein in Alzheimer's disease
S Barghorn et al.
JOURNAL OF NEUROCHEMISTRY (2005)
β-site specific intrabodies to decrease and prevent generation of Alzheimer's Aβ peptide
P Paganetti et al.
JOURNAL OF CELL BIOLOGY (2005)
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor proteintransgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β
MM Racke et al.
JOURNAL OF NEUROSCIENCE (2005)
Intrabody applications in neurological disorders: Progress and future prospects
TW Miller et al.
MOLECULAR THERAPY (2005)
Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β
M Hoshi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
R Kayed et al.
SCIENCE (2003)
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide:: a case report
JAR Nicoll et al.
NATURE MEDICINE (2003)
Neurodegenerative disease - Amyloid pores from pathogenic mutations
HA Lashuel et al.
NATURE (2002)
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
RB DeMattos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
分享论文
